The ASCENT study (NCT01553942) is the only clinical trial reporting the outcomes of the preoperative use of second-generation EGFR-TKIs for treatment of EGFR-mutated locally progressive NSCLC (LV et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.